Ocumension Therapeutics (HKG:1477) obtained approval to carry out a real world study of OT-703 (ILUVIEN) in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China, a Tuesday Hong Kong bourse filing said.
OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema.
In April 2021, the drugmaker had obtained exclusive licensed rights from Alimera Sciences for the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.